Glucocorticoid-induced osteoporosis and vertebral fracture are common complications in patients on glucocorticoid treatment for rheumatological diseases. The present study aimed to identify the risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis. This study included 225 Japanese women with glucocorticoid-induced osteoporosis and 72 patients with postmenopausal osteoporosis. All participants were treated with bisphosphonate or denosumab for osteoporosis with active form of vitamin D for at least 3 years. The differences of clinical parameters, including age, disease duration, body mass index (BMI), bone mineral density (BMD), and the dose and treatment duration of glucocorticoid were assessed between patients with and without vertebral fracture. Multivariate logistic regression analysis was also performed to evaluate the association of vertebral fracture with clinical parameters. The significant differences related to age, BMD of the hip, disease duration, glucocorticoid treatment duration between patients with and without vertebral fractures were demonstrated. The present study indicated that disease duration, BMI, and the total hip BMD were independent risk factors for vertebral fractures in patients with glucocorticoid-induced osteoporosis. Prolonged disease duration, low BMI, and low total hip BMD could be risk factors of vertebral fracture in patients on glucocorticoid treatment for rheumatological diseases.

中文翻译：

---

日本女性糖皮质激素性骨质疏松症患者椎体骨折的危险因素评估。


糖皮质激素引起的骨质疏松和椎体骨折是糖皮质激素治疗风湿病患者常见的并发症。本研究旨在确定日本女性糖皮质激素引起的骨质疏松症患者椎体骨折的危险因素。这项研究包括 225 名患有糖皮质激素引起的骨质疏松症的日本女性和 72 名绝经后骨质疏松症患者。所有参与者均接受双磷酸盐或狄诺塞麦治疗骨质疏松症以及活性维生素 D 至少 3 年。评估有和没有椎骨骨折患者的临床参数差异，包括年龄、病程、体重指数（BMI）、骨矿物质密度（BMD）以及糖皮质激素的剂量和治疗持续时间。还进行了多变量逻辑回归分析来评估椎骨骨折与临床参数的关联。椎体骨折患者与非椎体骨折患者之间的年龄、髋部 BMD、病程、糖皮质激素治疗持续时间存在显着差异。本研究表明，病程、BMI和总髋部BMD是糖皮质激素性骨质疏松症患者椎体骨折的独立危险因素。病程长、BMI低和髋部总BMD低可能是接受糖皮质激素治疗风湿病患者椎体骨折的危险因素。